Sanofi (NASDAQ:SNY) said on Thursday its multiple myeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial.
The drug is currently indicated for use in a combination therapy for previously-treated relapsed or refractory multiple myeloma. The Phase 3 IMROZ trial showed it achieved the primary endpoint of progression free survival in transplant-ineligible patients with newly diagnosed multiple myeloma.
Sarclisa – combined with bortezomib, lenalidomide and dexamethasone – significantly reduced the risk of disease progression or death compared with just dexamethasone.
Dietmar Berger, global head of development, Sanofi, said: “This is the second Phase 3 trial investigating Sarclisa in newly diagnosed patients to show superiority versus standard of care, reinforcing our belief in Sarclisa as a best-in-class medicine. These data underscore our commitment to advancing scientific innovation for people living with multiple myeloma, and we look forward to sharing more detail on Sarclisa’s potential to improve outcomes for patients receiving earlier lines of therapy.”
Sanofi (SNY) licensed isatuximab from Immunogen (IMGN) in 2017 as part of an exclusive deal.
